Biosafety

Henley Ion Announces Promising Technology Developed to Protect Against COVID-19 and Emerging Variants

Retrieved on: 
Wednesday, January 12, 2022

The objective of our efforts at Henley Ion is to provide people with the means to protect themselves from airborne pathogens.

Key Points: 
  • The objective of our efforts at Henley Ion is to provide people with the means to protect themselves from airborne pathogens.
  • Additional evaluations are ongoing at the Tulane facility under a cooperative research agreement between Henley Ion and the university.
  • The number one mission at Henley Ion is to save lives, says Skipper Bond, CEO of Henley Ion.
  • Questions about Henley Ion, the mEP technology, or licensing matters can be directed to Mr. Skipper Bond, CEO of Henley Ion at (504) 323-8129 or [email protected].

T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial

Retrieved on: 
Tuesday, January 11, 2022

The T2Biothreat Panel, which runs on T2 Biosystems T2Dx Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including B. anthracis, F. tularensis, Burkholderia spp., Y. pestis,and R. prowazekii.

Key Points: 
  • The T2Biothreat Panel, which runs on T2 Biosystems T2Dx Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously detects six biothreat pathogens identified as threats by the U.S. Government, including B. anthracis, F. tularensis, Burkholderia spp., Y. pestis,and R. prowazekii.
  • We are pleased to initiate the clinical trial for our novel T2Biothreat Panel as we continue to advance our product development strategy ahead of schedule, said John Sperzel, Chairman and CEO at T2 Biosystems.
  • T2 Biosystems products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR) technology.
  • T2 Biosystems has an active pipeline of future products, including the T2Cauris Panel, and T2Lyme Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.

Jacobs Wins Project Management Award for Abu Dhabi Wastewater Lab

Retrieved on: 
Thursday, September 9, 2021

DALLAS, Sept. 9, 2021 /PRNewswire/ -- Jacobs (NYSE:J) was awarded a two-year contract from the Abu Dhabi Department of Energy for project management of a wastewater laboratory that will screen and detect for COVID-19 and other infectious diseases.

Key Points: 
  • DALLAS, Sept. 9, 2021 /PRNewswire/ -- Jacobs (NYSE:J) was awarded a two-year contract from the Abu Dhabi Department of Energy for project management of a wastewater laboratory that will screen and detect for COVID-19 and other infectious diseases.
  • "This project will help empower public health officials and the Abu Dhabi community by using evidence-based tools, likeartificial intelligence,to screen wastewater for pathogens, pollutants and other indicators of human health,"saidJacobs People & Places Solutions EVP and President Patrick Hill.
  • Jacobs will oversee project execution and supervise the design, engineering, procurement and construction of the lab.
  • "The Wastewater Monitoring Lab is a remarkable initiative and a step forward in our continuous efforts to protect the public health of the people of Abu Dhabi," said Director of Executive Affairs at the Abu Dhabi Department of Energy and Wastewater Monitoring Lab Project Director Saeed AlMehairbi.

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

Retrieved on: 
Monday, August 2, 2021

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.

Key Points: 
  • SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.
  • This certificate demonstrates WuXi Biologics' compliance to global cGMP biosafety testing standards and regulatory guidelines.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "The second EMA certificate is the solid proof of our world-class quality system as well as the technology platforms utilized at our Suzhou facility.
  • WuXi Biologics Biosafety Testing team offers cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials.

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

Retrieved on: 
Monday, August 2, 2021

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.

Key Points: 
  • SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.
  • This certificate demonstrates WuXi Biologics' compliance to global cGMP biosafety testing standards and regulatory guidelines.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "The second EMA certificate is the solid proof of our world-class quality system as well as the technology platforms utilized at our Suzhou facility.
  • WuXi Biologics Biosafety Testing team offers cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials.

Spirit Airlines to Add Third Vacation Destination in Mexico with Nonstop Flights to Puerto Vallarta Starting in July

Retrieved on: 
Wednesday, March 31, 2021

Spirit will also add nonstop service between LAX and Los Cabos, Mexico (SJD) starting May 5.

Key Points: 
  • Spirit will also add nonstop service between LAX and Los Cabos, Mexico (SJD) starting May 5.
  • The route will be Spirit's first international service from Los Angeles, which will be joined by Puerto Vallarta when it launches the following month.
  • "In addition to the biosafety protocols and destination policies, they have made tourism safe and welcomes Guests with pleasure.
  • In January, the carrier launched its new Free Spirit loyalty program, which is the fastest way to earn rewards and status.

NBA, NFL, NHL and MLS Teams Choose Biosafety Startup, R-Zero, as their UV-C Disinfection Solution

Retrieved on: 
Monday, March 8, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210308005112/en/
    R-Zero's Arc at Golden 1 Center in downtown Sacramento, California.
  • With Arc, which retails at a fraction of the price of traditional UV-C solutions, R-Zero is effectively disrupting a legacy industry.
  • Unlike chemical disinfection, on which sports facilities have traditionally relied, Arc is eco-friendly, highly effective, and addresses airborne pathogens.
  • R-Zero is the first biosafety company dedicated to making the spaces we all live, learn, work, and play safer and clinically clean.

TOMI Environmental Completes Study With University of Virginia Demonstrating Its Disinfection Unit Achieves Kill on SARS CoV-2 Virus in 5 Seconds

Retrieved on: 
Wednesday, January 27, 2021

There was reduction in the number of SARS CoV-2 PFUs in all exposure methods used to the point where there was no detectable viable coronavirus.

Key Points: 
  • There was reduction in the number of SARS CoV-2 PFUs in all exposure methods used to the point where there was no detectable viable coronavirus.
  • The successful study was conducted at the University of Virginias Biosafety Level 3 facility, which is approved for Select Agent research by the Centers for Disease Control and Prevention.
  • Represented by the SteraMist brand of products, iHP produces a germ-killing aerosol that works like a visual non-caustic gas.
  • We undertake no obligation to update these forward-looking statements after the date of this release.

R-Zero Poised to be a Breakthrough Leader in Enterprise Biosafety with Record Sales in First Year

Retrieved on: 
Thursday, January 14, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210114005863/en/
    R-Zero's Hospital-Grade UV-C Device, Arc, Destroys 99.99% of Surface and Airborne Pathogens.
  • The fact we did so with a hardware product makes this an even bigger accomplishment.
  • We believe were on a top-decile growth path, and looking at our future product roadmap, were confident R-Zeros best days are still ahead.
  • R-Zero is the first biosafety company dedicated to making the spaces we all live, learn, work, and play safer and clinically clean.